AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 09:05:02 15/07/2024 pm IST			5-day change	1st Jan Change
12,104 ^GBX	-1.27%		+0.50%	+14.19%

15/07	Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast...
15/07	AstraZeneca: acquisition of Amolyt Pharma finalized	CF

ASTRAZENECA : Gets a Neutral rating from Deutsche Bank

January 05, 2024 at 04:24 pm IST

In a research note published by Emmanuel Papadakis, Deutsche Bank gives a Neutral rating to the stock. The target price remains unchanged at GBX 11000.

Latest news about AstraZeneca PLC

Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast...	15/07
AstraZeneca: acquisition of Amolyt Pharma finalized	15/07	CF
AstraZeneca Closes $1.05 Billion Amolyt Pharma Acquisition	15/07	MT
AstraZeneca PLC completed the acquisition of Amolyt Pharma SAS for $1.05 billion.	15/07	CI
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca	13/07	DJ
Sector Update: Health Care Stocks Mixed Premarket Friday	12/07	MT
Instil Bio Signs Lease With AstraZeneca Pharmaceuticals at California Facility; Shares Rise After Hours	12/07	MT
ASTRAZENECA : Deutsche Bank reiterates its Neutral rating	10/07	ZD
Barclays raises Kerry, cuts Hunting, Wood Group	10/07	AN
ASTRAZENECA : JP Morgan reaffirms its Buy rating	10/07	ZD
AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	05/07	MT
AstraZeneca: cancer treatment approved by the EU	05/07	CF
AstraZeneca drug Tagrisso gets EU approval for cancer form	05/07	AN
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment	05/07	MT
ASTRAZENECA : Goldman Sachs maintains a Buy rating	04/07	ZD
ASTRAZENECA : Buy rating from Berenberg	03/07	ZD
Aptamer shares jump as inks agreement with AstraZeneca	03/07	AN
Aptamer Group plc Announces New Agreement with AstraZeneca to Evaluate the Optimer Fibrotic Liver Delivery Vehicles for the Targeted Delivery of SiRNA	03/07	CI
ASTRAZENECA : Jefferies reaffirms its Neutral rating	02/07	ZD
Deutsche Bank cuts Quilter, ups Polar Capital	02/07	AN
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June	01/07	MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone	01/07	MT
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment	01/07	MT
AstraZeneca's Imfinzi, Lynparza Combination Recommended for Approval in Europe as Endometrial Cancer Treatment	01/07	MT
AstraZeneca applies to the EMA for a Covid antibody	01/07	CF

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 09:32 pm IST

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

157.2 USD

Average target price

177.6 USD

Spread / Average Target

+13.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+14.19%	244B
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.42%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ROCHE HOLDING AG	+5.81%	234B
NOVARTIS AG	+16.77%	226B
AMGEN INC.	+14.63%	177B
PFIZER, INC.	+1.08%	165B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Gets a Neutral rating from Deutsche Bank

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals